Biotechnology
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
BEIJING and BOSTON, June 22, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens o...
2021-06-23 04:16
1547
Mina J. Bissell Ph.D. & Vectorspace AI Advance New Space Biosciences Division
SAN FRANCISCO, June 23, 2021 /PRNewswire/ -- As the new space race heats up, more humans will be traveling into space than ever before. Spaceflight causes many changes in human health. Humans cannot be sent into space without understanding how to protect and repair human DNA along with tissue re...
2021-06-23 03:16
1664
Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia
SHENZHEN, China, June 22, 2021 /PRNewswire/ -- On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated inMalaysia, and the first batch ...
2021-06-22 22:32
9436
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
ST. CHARLES, Mo., June 22, 2021 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (EUFI.PA) company, and ImmunoPrecise Antibodies (Nasdaq:IPA), the market leader in full-service therapeutic discovery and deve...
2021-06-22 20:28
3848
Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results
HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial ...
2021-06-22 19:00
24280
European Wellness Advances Clinical Trials on Precursor Stem Cells for Fertility and Immunology into China
KOTA KINABALU, Malaysia, June 22, 2021 /PRNewswire/ -- European Wellness Biomedical Group (European Wellness) has signed a memorandum of understanding (MOU) with Li Hua Biotechnology to formalize strategic alliance in scientific research and clinical trials development for fertility and immunolog...
2021-06-22 14:14
2715
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement
SAN FRANCISCO and SUZHOU, China, June 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-22 08:00
18582
The Pressing Need for Early Detection of Mucormycosis during COVID-19
DONGGUAN, China, June 21, 2021 /PRNewswire/ -- Mucormycosis or black fungus, a
devastating infection that soars inIndia during COVID-19 has seized global
attention. Recently, the country's mucormycosis cases reached over 57,150 and
resulted in54% mortality
2021-06-21 20:00
3602
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-06-21 19:00
7293
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-06-21 08:00
6240
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.
NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...
2021-06-20 21:00
2864
CARsgen Therapeutics officially listing on HKEX
HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited
(the "Company", stock code: 2171.HK) today announced that the Company's Shares
have been traded on the Main Board of The Stock Exchange of Hong Kong Limited
under the stock code "2171.HK".
2021-06-19 02:57
9284
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...
2021-06-18 17:12
13768
China and India Combat Coronavirus Pandemic Together: Online Ceremony Held for the Handover of Medical Supplies to Aid India
HONG KONG, June 18, 2021 /PRNewswire/ -- On 11 June 2021, an online ceremony was held for the handover of anti-pandemic supplies to aidIndia. Medical supplies toIndia included 135 oxygen concentrators, 5 ventilators and 3,300 KN95 masks. Present at the event were Tang Guocai, Chinese Consul Gener...
2021-06-18 16:15
1920
Antengene Provides an Update on Its Latest Developments
* Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 monoclonal antibody, and ATG-027, a potential first-in-class B7H3/PD-L1 bi-specific antibody * Provides an update on commercial readiness across the Asia Pacific markets for selinexor, Antengene's f...
2021-06-18 14:10
11943
Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)
HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®# (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...
2021-06-18 10:00
2203
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
SINGAPORE, June 18, 2021 /PRNewswire/ -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed$24 million Series A financing round. The round was co-led by EVX Ventures andBoehringer Ingelheim Venture Fun...
2021-06-18 09:58
7345
Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board
SHANGHAI, June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage
biopharmaceutical company focused on discovery and development of metabolic and
immunologic therapeutics, announced today the addition ofJacques Mizrahi,
Ph.D., to its scientific advisory board.
2021-06-17 19:49
2185
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...
2021-06-17 15:41
13820
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
BEIJING, June 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) ...
2021-06-17 11:31
14156
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
